← All trials
NCT04768608
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 31, 2021
- Primary completion
- Feb 28, 2023
- Completion date
- Jan 31, 2024
- First posted
- Feb 24, 2021
- Last posted
- Aug 20, 2021
- Enrollment
- 18
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Zhejiang UniversityLead sponsor
- Zhejiang UniversityOverall official - principal investigator
- Zhejiang UniversityReponsible party - principal investigator
- Shanghai Bioray Laboratory Inc.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.